ClearPoint Neuro, a global therapy-enabling platform, and quality treatment empowering organization offering exact route to the brain and spine, declared it has secured 510(k) approval for its Prism Bone Anchor Accessory. The company's second new...
Pfizer Inc, a pharmaceutical industry firm and Genmab A/S reported that the US Food and Drug Administration (FDA) endorses the supplemental Biologics License Application (sBLA) giving full endorsement for Tivdak (tisotumab vedotin-tftv) for the...
The US FDA endorsed the utilization of a sprinkle case plan of Neurocrine Biosciences Ingrezza (valbenazine) for the treatment of tardive dyskinesia and chorea in Huntington's illness. The US FDA endorsed the utilization of a sprinkle case plan.....
Japanese Astellas Pharma Inc. and Poseida Therapeutics, Inc. declared that Xyphos Biosciences, Inc., and Poseida have gone into a research collaboration and permit consent to foster novel convertibleCAR® programs by consolidating the creative cell...
TriLink BioTechnologies, a Maravai LifeSciences company that provides global life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, an international development and manufacturing partner for the...
Bio-Techne Enterprise, a biotechnology firm, declare a critical achievement in its obligation to giving state of the art solutions for its users. With effective from May 1, 2024, the firm will foray into an strategic distribution deal with Thermo...
Ono Pharmaceutical, a leading Japanese pharma firm, intends to make its largest acquisition to date, purchasing an American cancer drug manufacturer for $2.4 billion. The company is looking for growth through new drug candidates As the Opdivo...
Strengthening its road safety initiatives, Maruti Suzuki India Limited had partnered with AIIMS, India’s premier medical institute, and International Road Federation (IRF) to provide first aid and trauma care training to commercial drivers
American Oncology Institute (AOI) in Mangalagiri proudly announces a groundbreaking advancement in the treatment of breast cancer. Recently, AOI successfully treated three high-risk patients with carcinoma breast
The US FDA has approved its treatment for patients over 12 with a rare genetic immunodeficiency disease, per X4 Pharmaceuticals. X4's mavorixafor, to be sold under the brand name Xolremdi, is the primary treatment to get U.S. endorsement...
, CDSCO.jpg)
